Anti-Vβ17 Bispecific Antibodies for Targeted T Cell Redirection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to modulate immune responses specifically targeting T Cell Receptor Beta Variable 17 (Vβ17) for therapeutic applications, particularly in modulating T cell activity and targeting specific antigens or epitopes on T cells and other target cells.
Innovation Solution
Development of anti-Vβ317 antibodies, including bispecific antibodies, that bind to Vβ17 and additional targets such as CD123, BCMA, DLL3, PSMA, or KLK2, with specific CDR sequences for enhanced binding capabilities, and use of nucleic acids and expression vectors to produce these antibodies for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current technologies are used for immune modulation, then general immune response can be affected, but specific targeting of Vβ17 and T cell activity modulation cannot be achieved
Solution Approach 1:
The patent applies local quality by designing antibodies with specific CDR sequences (VH CDR1: SEQ ID NO:21, VH CDR2: SEQ ID NO:677, VH CDR3: SEQ ID NO:1032, VL CDR1: SEQ ID NO:1064, VL CDR2: SEQ ID NO:1096, VL CDR3: SEQ ID NO:1128) that are tailored to bind specifically to Vβ17 on T cells. This localized specificity at the molecular binding interface enables precise targeting of Vβ17-expressing T cells without affecting other T cell subsets, resolving the contradiction between achieving specific immune modulation and having effective therapeutic methods available.
Solution Approach 2:
The patent employs parameter changes by modifying the antibody structure through specific CDR sequences to alter binding affinity and specificity for Vβ17. The defined CDR regions create an antibody with optimized parameters for Vβ17 recognition, enabling specific T cell modulation. This parameter optimization transforms the inability to specifically target Vβ17 into an effective therapeutic capability with precise T cell activity modulation.
2Object-affected harmful factors
If non-specific immune modulation is used, then broad immune effects occur, but specific T cell targeting and growth inhibition cannot be achieved
Solution Approach 1:
The patent introduces an intermediary molecule - the anti-Vβ17 antibody with specific CDR sequences - that mediates between the immune system and target cells. This antibody acts as a selective intermediary that binds to Vβ17 on T cells and redirects them to target cancer cells expressing secondary antigens. This intermediary approach eliminates uncontrolled immune effects by providing specific Vβ17-directed modulation while maintaining reliable therapeutic efficacy through precise T cell targeting and activation.
Solution Approach 2:
The patent applies segmentation by dividing the immune response into specific Vβ17-targeted T cells and other T cell populations. The antibody specifically segments the immune effectors by binding only to Vβ17-expressing T cells, enabling selective activation and redirection of this subset against cancer cells. This segmentation resolves the contradiction by preventing broad uncontrolled immune effects while ensuring reliable therapeutic action through focused Vβ17-specific T cell engagement.
3Ease of operation
If conventional antibody approaches are used, then general antigen binding is possible, but enhanced binding capability and T cell redirection to specific targets cannot be achieved
Solution Approach 1:
The patent applies universality by designing the anti-Vβ17 antibody to perform multiple functions simultaneously: (1) binding to Vβ17 on T cells, (2) redirecting T cells to target cells expressing secondary antigens, and (3) enhancing T cell activation and cytotoxicity. The bispecific antibody structure enables these multiple functions through its dual antigen recognition capability, resolving the contradiction between simple antibody binding and high productivity in T cell-mediated cancer cell killing.
Solution Approach 2:
The patent employs composite materials by creating a bispecific antibody that combines two different antigen-binding specificities in a single molecular structure. This composite antibody contains both the Vβ17-binding domain (with specific CDR sequences) and the secondary antigen-binding domain, enabling simultaneous engagement of T cells and target cells. This composite structure achieves enhanced binding capability and T cell redirection efficiency while maintaining the operational simplicity of a single antibody molecule.
Data Source
AI summary
Anti-Vβ17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.